Search in the Abstract Database

Search Abstracts 2011

* = Presenting author

P355. Prevalence of new serological markers in an old Irish IBD cohort

M.N. Shuhaibar1,2, C. O'Morain1,2

1Adelaide and Meath Hospital incorporating the National Children Hospital, Dublin 24, Ireland; 2Trinity College Dublin, Dublin, Ireland

Aim: To evaluate the recently available inflammatory bowel disease serological markers assay prevalence in a prospective Irish population cohort from the early 1990s with ulcerative colitis and Crohn's disease that was part of the European Collaborative on IBD (EC-IBD).

Materials and Methods: Patients from the original collected database between 1991–1993, were recontacted following the ethical approval of each of the 10 respective hospitals in the greater Dublin area. Patients attended for an interview where they were asked to complete questionnaires in order to assess IBD disease course, outcomes, disease activity and its effect on their quality of life. Patients were also asked to volunteer a blood sample for serological marker analysis. Over a six month period samples were collected from 111 consenting original patients and 4 were excluded. The analysis was performed using the commercially available glycominds ELISA kits. These are the initial results for laminaribioside (ALCA), chitobioside (ACCA), and mannobioside (AMCA) antibodies.

Results: There was higher sensitivity and specificity noted in the anti laminaribioside carbohydrate antibodies (ALCA) in our cohort with 18/107 patients testing positive. Of those, 12 had UC and 6 had CD. However, 90 patients were negative for ALCA. Anti-chitobioside carbohydrate antibodies (ACCA), tested positive in 9/107 IBD patients, 5 UC and 4 CD patients. For the anti-mannobioside carbohydrate antibodies (AMCA) only 2 patients tested positive when adopting manufacturer reference ranges.

Conclusions: Over 80% of the Irish cohort AMCA, ALCA, ACCA serological markers seem to have negative results, however those results confirm that an isolated marker has a limited benefit and should be incorporated togather along with the phenotyping and genotyping for those patients.